Navigation Links
Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
Date:6/2/2008

patient instruction, and insulin dose adjustments are critical elements for reducing this risk. This information is highlighted in a boxed warning in the SYMLIN prescribing information for healthcare professionals and in a medication guide for patients, which will be distributed by pharmacists.

Other adverse events commonly observed with SYMLIN when co-administered with insulin were mostly gastrointestinal in nature, including nausea, which was the most frequently reported. The incidence of nausea was higher at the beginning of SYMLIN treatment and decreased with time in most patients. The incidence and severity of nausea are reduced when SYMLIN is gradually increased to the recommended doses.

About BYETTA

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has been used by approximately one million patients since its introduction. For full prescribing information, visit http://www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommend
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
2. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
3. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
4. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
5. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals to Webcast First Quarter Results
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
10. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
11. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SAN FRANCISCO, Calif. , Aug. 31, 2015 /PRNewswire/ ... the discovery and development of novel cancer immunotherapies, announced ... M.D., Ph.D., as Chief Executive Officer and William ... Wong and Ho join an experienced management team led ... Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... , ... August 31, 2015 , ... There’s a new ... Minerva is the first commercially available new FDA approved system in the last 14 ... of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction ...
(Date:8/28/2015)... ... 28, 2015 , ... Proove Biosciences , a commercial ... Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM event ... focus on evidence-based research and clinical application, the event gathered industry thought leaders ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
Breaking Biology Technology:FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") ... ended July 31, 2011. Third - ... and Recent Events Net sales increased 33.6% ...
... Inc. (Nasdaq: SGMO ) announced today that ... overview of the company,s business strategy at 7:30 am ... 2011 Global Life Sciences Conference which will be held ... Nichol, M.B., Ch.B., Sangamo,s executive vice president of research ...
... Pa., Sept. 14, 2011 Tengion, Inc. (NASDAQ: ... Brian Davis, Vice President Finance and Chief Financial Officer of ... Conference on Monday, September 19, 2011, at 1:30 pm EDT. ... be accessed under "Calendar of Events" in the Investors section ...
Cached Biology Technology:China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 2China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 3China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 4China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 5China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 6China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 7China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 8Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference 2Tengion to Present at UBS Global Life Sciences Conference 2
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... an essential nutrient similar to the B vitamin and found ... eggs, when given as a dietary supplement in the last ... a lower rate of physiological schizophrenic risk factors in infants ... its potentially therapeutic findings and in its strategy to target ...
... In addition to causing smoggy skies and chronic coughs, soot ... number two contributor to global warming. It,s second only to ... panel., The new study concludes that black carbon, the soot ... to global warming as previously estimated, even by the 2007 ...
... HONOLULU While the iconic Haleakalā silversword plant made a ... a period of substantial climate-related decline. New research published this ... the silversword in its native habitat. Known for its ... single reproductive event at the end of its life, at ...
Cached Biology News:Choline supplementation during pregnancy presents a new approach to schizophrenia prevention 2International study: Where there's smoke or smog, there's climate change 2International study: Where there's smoke or smog, there's climate change 3Global warming may have severe consequences for rare Haleakalā silverswords 2
Glycerokinase; from Bacillus stearothermophilus...
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... enzyme that catalyzes the conversion,of starch ... maltotriose and,dextrins. The level of a-amylase ... are of clinical importance,1-3 while plant ... industry.4, The EnzChek Amylase Assay Kit ...
Biology Products: